Komatsu | Thanos | Hadjiargyrou
The overall goal of this research was to determine if methyphenidate (MP), sold as Ritalin, is harmful to skeletal development and if so, how to reduce its adverse effects.

This research extends previous research finding that chronic exposure of methylphenidate (MP) in adolescent rats was detrimental to development and utilized the novel two-bottle oral dosing method that provides in rats an MP pharmacokinetic profile to that observed clinically. The research team used a multidisciplanary approach to looking at behavioral, neurochemical and skeletal response to a chronic exposure to MP in both males and females as well as determine if alternative dosing protocols can mitigate the adverse effects of MP on development.

Principal Investigator
David Komatsu
Stony Brook University

Co-Investigators
Panayotis (Peter) K. Thanos, PhD
Research Institute on Addictions

Michael Hadjiargyrou, PhD
New York Institute of Technology

Funding Agency
National Institute of Child Health & Human Development (NICHHD)

Grant Number
R01-HD07088

Dates
2013-2018